Next Phase Newsletter

A corporate venture capital arm of a global company seeks to make strategic investments into early-stage companies that are aligned with the parent company’s R&D focus. For equity investments, the firm will lead, co-lead, or participate in syndicated financings. With deep connections into the parent company’s global research and development centers, the firm is ideally placed to nurture innovative pharmaceutical companies and to connect these into the parent company.

The firm core focus is on therapeutics. Currently, the firm is most interested in oncology, gastrointestinal diseases, neuroscience and rare disease. The firm is also interested in breakthrough platforms technologies that improve peptide, antibody, cell, and gene based therapies. The firm does not invest in medical devices or diagnostics.

The firm’s primary focus is on start-up/seed rounds, through mid-stage financings – pre-clinical through Phase II. The firm respects the autonomy of the institutions it invests in and seeks standard institutional venture investment terms without special rights or options.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment firm headquartered in Japan is actively seeking investment opportunities in Seed to Series A rounds, and can invest up to $3M over the company’s lifecycle. The firm is open to companies based in Japan, USA, and Europe.

The firm is interested in cutting edge technologies in all areas of life sciences, and will consider all opportunities in therapeutics, medical devices, diagnostics, and digital health across all indications. As the firm is an early-stage investor, the firm will consider any technologies in pre-clinical stage of development.

The firm does not have specific company or management team requirements. The firm can act as either a lead or co-investor, but if the company is very early-stage, the firm will expect to have a more active role in supporting the company’s growth and will seek to act as the lead investor. In addition, the firm has partnered with numerous organizations and has a strong network the firm can leverage to provide operational/commercialization support.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based healthcare venture capital investment firm generally makes investments in early stage companies targeting healthcare technology and services. The investment size will vary, depending on the opportunity. The firm typically invests in companies based in the United States though is open to companies based on a global level.

In the healthcare technology sector, the firm is actively seeking new investments in healthcare software and tech-enabled services sectors with a specific focus on payment reform, patients as consumers, healthcare analytics, healthcare infrastructure, and novel service delivery models. The firm has a specific interest in transformational technologies and services that enable value-based healthcare. The firm currently is not focused on therapeutics or traditional medical device investment opportunities, though may consider medical devices with a software/data component, such as sensors, that have either already obtained FDA clearance or are not subject to FDA regulation. The firm is indication agnostic and invests in pre-revenue to growth stage products.

The firm  seeks to invest in privately held companies with a strong and experience management team. The group prefers to invest in companies with cutting-edge technologies and large market potential.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Venture Capital firm with offices in the USA closed their first fund in 2014 and is currently working on their second fund. The firm has approximately 40 active investments in the biotech space. The firm mostly invests in Seed to Series B primarily but has and will consider later stage funding depending upon the merits of each deal structure.  The firm will consider a seed investment of $250k – $1 million for Seed.  Typical funding sizes for Series A & B are dependent upon the deal but generally $5 million and beyond. The firm is open to investing in companies worldwide and remain agnostic to space and disease.

The firm invests exclusively in the Life Science space and is looking for new investment opportunities in the therapeutics, medical devices, diagnostics, and selective digital health sectors. The firm is opportunistic in terms of sub-sectors and indications, including all classes of medical devices, as well as all phases of development for therapeutics.

The firm is open to all types of management teams but like to see highly motivated entrepreneurs who are looking to lead monumental healthcare change and with management teams that have serial startup drives with whom they can build long term partnerships. The firm is open to both leading, co-leading, or participating in syndicates depending on the company and deal structure.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The drug development company was founded in 2016 and is headquartered in the US. In 2016, they closed a $49 M fund to in-license 4-6 IND-ready assets and develop them through Phase 2b. After proof-of-concept is established, they will seek to exit. Roughly 90% of the fund will be used to fund development, with clinical trials carried out by the firm. They are particularly interested in therapeutics falling in the sectors of neuroscience and immunology.

The firm is seeking small molecules and biologics in the areas of neuroscience and immunology that can improve patient lives. They do not consider drugs for highly crowded spaces, for example oncology or disease-modifying drugs for Alzheimer’s. Levadopa-induced dyskinesia in Parkinson’s and ataxia have been areas of interest, and they will consider therapeutics for orphan and rare diseases. Drug platforms addressing self-similar indications/targets are also of interest.

The firm looks for IND-ready drugs that can be developed or re-purposed, and will conduct a thorough due diligence taking 6 months to a year. The opportunity should have a clear regulatory and development pathway and good prospects for an exit within 4 years of acquisition. With strong scientific backgrounds themselves, the firm respects the expertise of the innovators. They will work with founders to arrange a deal, and are open to negotiating option agreements.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The venture fund is based Spain and invests in early stage companies in the life sciences and Information Technology Sectors. The firm also invests in public companies through Convertible Bonds and secondary alternative markets. The firm also offers Venture Debt financing for private companies. Within Life Sciences, the firm invests in rounds of EUR 2-8 Million Seed and Series A rounds. The firm invests in Europe and North America.

In the life sciences, the fund focuses on therapeutics and also CDMOs, medical devices, healthcare and Digital Health. In therapeutics, the firm focuses on preclinical opportunities with a focus on assets that are 12-18 months prior to IND. Outside of Therapeutics, the fund invests in companies that are revenue positive. The fund generally does not invest in large indication areas such as diabetes, metabolic disease, cardiovascular and renal disease. The firm’s areas of interest include oncology, CNS, dermatology, and ophthalmology (particularly front of eye diseases). The firm has invested in rare diseases but it is not the firm’s sole focus.

In therapeutic opportunities, the firm seeks companies that have obtained proof of concept data in animal studies and can reach human clinical trials with financial needs of up to EUR 8 million to reach a human Proof of Efficacy. In Spain, the firm typically leads investment rounds, and may syndicate

with other firms or leverage public funding. In North America, the firm seeks to co-invest in rounds led by top-tier Venture Capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.